Mouse Monoclonal p21 antibody. Carrier free. Suitable for IHC-P, ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CDKN1A.
pH: 7.2 - 7.4
Constituents: 100% PBS
IHC-P | ICC | WB | |
---|---|---|---|
Human | Tested | Tested | Tested |
Mouse | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 2-4 µg/mL | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species Rat | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1-2 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1-2 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest (PubMed:9106657). Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Also involved in p53-independent DNA damage-induced G2 arrest mediated by CREB3L1 in astrocytes and osteoblasts (By similarity). Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D-CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739). Negatively regulates the CDK4- and CDK6-driven phosphorylation of RB1 in keratinocytes, thereby resulting in the release of E2F1 and subsequent transcription of E2F1-driven G1/S phase promoting genes (By similarity).
CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1, CDKN1A, Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, p21, MDA-6
Mouse Monoclonal p21 antibody. Carrier free. Suitable for IHC-P, ICC, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human CDKN1A.
pH: 7.2 - 7.4
Constituents: 100% PBS
This antibody s highly specific to p21 and shows no cross-reaction with other closely related mitotic inhibitors.
The p21 protein also known as CDKN1A is an important regulator of cell cycle progression. It acts as a cyclin-dependent kinase inhibitor where it binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes. The molecular weight of p21 is approximately 21 kDa. Cellular expression of p21 is diverse; it occurs in various tissues reflecting its broad role in maintaining cell cycle control. This protein's expression level is often assessed using techniques such as p21 western blotting p21 ELISA and p21 IHC staining.
P21 plays a critical role in cell cycle regulation and DNA damage response. It associates with the p53 tumor suppressor protein forming an essential part of the p53 signaling pathway under stress conditions. p21 arrests cells in G1 phase allowing DNA repair or leading to cellular senescence. Through these mechanisms p21 integrates signals from stress and damage emphasizing its importance as a mediator in cellular checkpoint control.
P21 is closely involved in the p53 and the Transforming Growth Factor-beta (TGF-β) signaling pathways. This integration helps in transmitting growth-inhibitory signals. p21 interacts with proteins such as p53 and cyclins ensuring precise regulation of the cell cycle and growth arrest when necessary. Triggered by p53 activation p21 contributes to preventing undisturbed cell proliferation acting as a safeguard against tumor formation.
P21's deregulation associates with cancer and age-related diseases. Its impairment is a common feature in many cancers often linked with defects in the p53 pathway. Reduced p21 expression can contribute to unchecked cell division and tumor progression. Moreover in age-related diseases p21's role in promoting cellular senescence connects it with degenerative conditions. The intricate relationship between p21 and proteins such as p53 and cyclins highlights its potential as a therapeutic target for these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunocytochemistry analysis of HeLa (human epithelial cell line from cervix adenocarcinoma) cells labeling p21 with ab212247 followed by Goat anti-Mouse IgG-CF555 (Red). Membrane stained with Phalloidin 488 (Green).
All lanes: Western blot - Anti-p21 antibody [CIP1/823] - BSA and Azide free (ab212247) at 2 µg/mL
All lanes: HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate
Predicted band size: 18 kDa
Observed band size: 21 kDa
Immunohistochemical analysis of formalix-fixed paraffin-embedded Human lung squamous cell carcinoma tissue, labeling p21 using ab212247 at 4 μg/mL.
Immunohistochemical analysis of formalix-fixed paraffin-embedded Human bladder carcinoma tissue, labeling p21 using ab212247 at 4 μg/mL.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-p21 antibody [CIP1/823] ab220206).
Western blot: Anti-CDKN1A antibody [CIP1/823] (Anti-p21 antibody [CIP1/823] ab220206) staining at 1 ug/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-p21 antibody [CIP1/823] ab220206 was shown to bind specifically to CDKN1A. A band was observed at 21 kDa in wild-type cell lysates with no signal observed at this size in CDKN1A knockout cell lines. To generate this image, wild-type and CDKN1A knockout cell lysates were analysed. CDKN1A knockout cell lines in HCT 116 (Human CDKN1A knockout HCT116 cell line ab288187), MCF7 (Human CDKN1A knockout MCF7 cell line ab288200) and A549 (Human CDKN1A knockout A549 cell line ab288213) backgrounds were used. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-p21 antibody [CIP1/823] (Anti-p21 antibody [CIP1/823] ab220206) at 1 µg/mL
Lane 1: Wild-type HCT 116 cell lysate at 20 µg
Lane 2: Western blot - Human CDKN1A knockout HCT116 cell line (Human CDKN1A knockout HCT116 cell line ab288187)
Lane 2: CDKN1A knockout HCT 116 cell lysate at 20 µg
Lane 3: Wild-type MCF7 cell lysate at 20 µg
Lane 4: Western blot - Human CDKN1A knockout MCF7 cell line (Human CDKN1A knockout MCF7 cell line ab288200)
Lane 4: CDKN1A knockout MCF7 cell lysate at 20 µg
Lane 5: Wild-type A549 cell lysate at 20 µg
Lane 6: Western blot - Human CDKN1A knockout A549 cell line (Human CDKN1A knockout A549 cell line ab288213)
Lane 6: CDKN1A knockout A549 cell lysate at 20 µg
All lanes: Goat anti-Mouse IgG H&L 800CW and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 18 kDa
Observed band size: 21 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com